Shattuck Labs

NSQ:STTK · US82024L1035

BiotechnologySmall

360

Medium confidence — indicative

Value—

Profit price84

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price22

Price/Sales15

Price/Book28

Quality41

Returns on capital41

Return on Capital37

Cash Return on Capital46

Return on Equity39

Profit margins45

Cash backing34

Accruals62

Owner Earnings Margin5

Growth46

Sales growth1

Profit growth76

Reinvestment1

Price momentum90

Safety44

Debt load52

Debt serviceability42

Refinancing83

Debt Payback1

Liquidity50

Sentiment68

Analyst ratings41

Expectations trend72

Opinion Changes50

Price Target Upside93

Market mood18

Value Creation6/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Shattuck Labs doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2016

Employees47

Websiteshattucklabs.com

ISINUS82024L1035

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Chronic DiseasesInflammationGastroenterologyImmunologyOncologyBiopharmaBiotechnologyLife Science

Description

Shattuck Labs, Inc., a biotechnology company, specializes in the development of potential treatments for inflammatory and immune-mediated diseases. The company is developing a potentially first-in-class antibody for the treatment of inflammatory bow…

Analysis

Middle-of-the-road

Shattuck Labs, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Shattuck Labs with its peers

Kymera Therapeutics

NMQ:KYMR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

ImageneBio

NAQ:IMA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Spyre Therapeutics

NSQ:SYRE

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zenas Biopharma

NSQ:ZBIO

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zura Bio

NAQ:ZURA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

RAPT Therapeutics

NMQ:RAPT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →